NICE approves Taxol for ovarian cancerBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7245.1293/a (Published 13 May 2000) Cite this as: BMJ 2000;320:1293
- Zosia Kmietowicz
The cytotoxic drug paclitaxel (Taxol) is to be made available to all women in Englandand Wales with ovarian cancer following the long awaited ruling by the National Institute for Clinical Excellence (NICE).
Paclitaxel, in combination with platinum, should be the first line treatment after surgery in all cases of ovarian cancer and should also be used to treat women whose cancer has recurred or has failed to respond to other forms of treatment, according to NICE.
The recommendation is expected to cost the NHS an additional £7m ($11.2m) a year to treat …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.